18F-FMISO

DRUG3 trials

Sponsors

Bernardino Clavo, MD, PhD, Memorial Sloan Kettering Cancer Center, University of Pennsylvania

Conditions

Malignant GliomaNon-Small-Cell-Lung Cancer (NSCLC)Soft Tissue Sarcoma

Phase 1

FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas

TerminatedNCT03730077

University of PennsylvaniaSoft Tissue Sarcoma

Start: 2019-02-01End: 2021-02-18Updated: 2021-03-18

Phase 2

FMISO-PET in Brain Tumors and SCS Effect

TerminatedNCT01868906

Bernardino Clavo, MD, PhDMalignant Glioma

Start: 2013-06-30End: 2017-09-17Updated: 2018-08-24

Unknown Phase

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

CompletedNCT02016872

Memorial Sloan Kettering Cancer CenterNon-Small-Cell-Lung Cancer (NSCLC)

Start: 2013-12-16End: 2024-07-08Updated: 2025-04-30

Related Papers

Reproducibility of <sup>18</sup>F-fluoromisonidazole intratumour distribution in non-small cell lung cancer.

2016-11-0725 citations